View Older Stories View More Recent Stories

Dec 10, 2025 09:16AM TD Cowen: 'Neurocrine Bio. (NBIX) Is a Top Biotech Pick'
Dec 8, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital
Dec 5, 2025 05:29AM Neurocrine Bio. (NBIX) PT Raised to $200 at TD Cowen
Nov 28, 2025 07:01AM Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Nov 26, 2025 06:52AM Neurocrine Bio. (NBIX) Won't Have to Contract Aggressively in 2027 - Stifel
Nov 20, 2025 08:30AM Neurocrine study highlights differences between tardive dyskinesia drugs
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 3, 2025 09:08AM Neurocrine Bio. (NBIX) PT Raised to $147 at BMO Capital
Oct 29, 2025 11:07AM Neurocrine Bio. (NBIX) PT Raised to $172 at Truist Securities
Oct 29, 2025 10:12AM Neurocrine Bio. (NBIX) PT Raised to $183 at Stifel
Oct 29, 2025 07:28AM Neurocrine Bio. (NBIX) PT Raised to $184 at Needham
Oct 29, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $174 at Jefferies
Oct 29, 2025 04:46AM Neurocrine Bio. (NBIX) PT Raised to $189 at Goldman Sachs
Oct 28, 2025 04:02PM Neurocrine Biosciences (NBIX) Tops Q3 EPS by 58c
Oct 21, 2025 05:01AM Citi Starts Neurocrine Bio. (NBIX) at Buy
Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'
Oct 17, 2025 08:30AM Neurocrine shares data on INGREZZA 40 mg treatment for tardive dyskinesia
Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview
Oct 9, 2025 09:38AM Neurocrine Bio. (NBIX) PT Raised to $195 at UBS
Oct 6, 2025 08:31AM Neurocrine shows 3-year safety data for Huntington's drug INGREZZA
Sep 23, 2025 08:30AM Neurocrine shows INGREZZA achieved tardive dyskinesia remission in 58% of patients
Sep 22, 2025 01:26PM Neurocrine Bio. (NBIX) PT Raised to $169 at Jefferies
Sep 22, 2025 09:44AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX), 'we await further derisking data'
Sep 22, 2025 07:39AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Sep 22, 2025 04:47AM UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Sep 5, 2025 05:23AM Neurocrine Bio. (NBIX) PT Raised to $149 at RBC Capital
Jul 31, 2025 09:52AM Neurocrine Bio. (NBIX) PT Raised to $175 at Guggenheim
Jul 31, 2025 08:53AM Neurocrine Bio. (NBIX) PT Raised to $145 at Mizuho
Jul 31, 2025 06:57AM Neurocrine Bio. (NBIX) PT Raised to $124 at BMO Capital
Jul 30, 2025 04:13PM Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
Jul 23, 2025 07:16AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Jul 21, 2025 07:32AM Truist Securities Starts Neurocrine Bio. (NBIX) at Buy
Jul 15, 2025 08:31AM Neurocrine shares registry data showing CAH treatment challenges
Jul 14, 2025 04:36PM Neurocrine presents one-year data showing weight improvements with CRENESSITY
Jul 14, 2025 08:31AM Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference
Jul 10, 2025 02:26AM Goldman Sachs Starts Neurocrine Bio. (NBIX) at Buy
Jul 9, 2025 05:59AM Neurocrine Bio. (NBIX) PT Raised to $174 at UBS
Jul 7, 2025 07:04AM Neurocrine starts phase 1 trial for experimental CAH treatment
Jun 27, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Post-Hoc Data Analyses from KINECT-HD Study
Jun 20, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA Capsules in Older Adults with Tardive Dyskinesia
Jun 9, 2025 04:05PM Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer
Jun 4, 2025 06:16AM Guggenheim Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Jun 2, 2025 06:58AM RBC Capital on Neurocrine Bio. (NBIX): 'We See Room for Additional Share Upside'
May 30, 2025 04:30PM Fate Therapeutics (FATE) names Matthew Abernethy to Board
May 28, 2025 04:07PM Neurocrine Biosciences (NBIX) Presents New Positive Data from Phase 2 Study of NBI-1117568
May 27, 2025 09:45AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
May 16, 2025 08:31AM Neurocrine Biosciences (NBIX) to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
May 16, 2025 08:26AM Neurocrine Biosciences (NBIX) Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
May 6, 2025 10:21AM Neurocrine Bio. (NBIX) PT Raised to $152 at UBS
May 6, 2025 09:55AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
View More Recent Stories View Older Stories